Navigation Links
Uroplasty Reports Third Quarter Fiscal 2009 Results
Date:2/3/2009

MINNEAPOLIS, Feb. 3 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the third quarter of fiscal 2009 ended December 31, 2008. Net sales for the third quarter of fiscal 2009 were $3.4 million versus $3.7 million during last fiscal year's third quarter.

"As we discussed in conjunction with the release of our fiscal second quarter results, our Urgent PC system to treat overactive bladder syndrome has been facing a challenging market environment created by insurance reimbursement uncertainties," said David Kaysen, President and CEO. "While a growing number of physicians are recognizing the benefits of Urgent PC, and the treatment continues to receive reimbursement from many insurance plans, our market momentum has slowed due to the uncertainty with insurance reimbursement.

"A major part of our strategy to expand and support third-party reimbursement coverage of Urgent PC treatment is the SUmiT study, which we announced in October. The study is designed to directly compare the effectiveness of Urgent PC treatment to non-active treatment and the enrollment of 221 patients was completed two months ahead of schedule," added Mr. Kaysen. The SUmiT study is evaluating reductions in urinary urgency, urge incontinence and frequency of urinary voids, as well as patient quality of life measures. This study, now expected to be completed by late summer of 2009, is taking place at 23 urology and urogynecology centers across the United States.

"Meanwhile, U.S. sales of Macroplastique are building momentum," added Mr. Kaysen. "Through our expanded sales focus and training, we are capitalizing on recent market concerns regarding competitive pro
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... 23, 2014 The report ... as its definition, classification, application and industry ... manufacturing process, and product cost structure. Production ... The analysis also covers upstream raw materials, ... development trend and proposals. In the end, ...
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... YORK, June 18 Danube Pharmaceuticals, Inc., a,privately ... development of innovative drugs for ophthalmology, is pleased,to ... MBA as its Chief,Executive Officer., "I am ... this,inflection point in its history as it advances ...
... CHESHIRE, Conn., June 18 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... Officer of Alexion Pharmaceuticals, will present at the,Jefferies & ... at 4:15,p.m., ET on Wednesday, June 25, 2008., ... available live. You can,access the webcast at: http://www.alexionpharm.com ...
... N.J., June 18 HemoCue(R) AB, a,global point-of-care ... Diagnostics Incorporated (NYSE: DGX ), today announced,that ... quantitative point-of-care,test for screening for, diagnosing and monitoring ... U.S. Food and Drug Administration (FDA). With,the FDA ...
Cached Biology Technology:Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... PITTSBURGHAn international study based at the University of Pittsburgh ... can biodegrade carbon nanotubesthe superstrong materials found in products ... potentially damaging health effects of being exposed to the ... Nature Nanotechnology . The results could open the ...
... the University of Pittsburgh provides the first identification of ... materials found in products from electronics to plasticsand in ... being exposed to the tiny components, according to findings ... results could open the door to the use of ...
... leading bat expert with the USDA Forest Service,s Southern Research ... Carolina, South Carolina and Tennessee that she believes are most ... and appears to be rapidly spreading south from the northeastern ... has been confirmed in Tennessee, and she says it is ...
Cached Biology News:Pitt-led international study identifies human enzyme that breaks down potentially toxic nanomaterials, opens door to novel drug delivery 2Pitt-led international study identifies human enzyme that breaks down potentially toxic nanomaterials, opens door to novel drug delivery 3Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 3Deadly fungus threatens 9 bat species in Ga., Ky., N.C., S.C. and Tenn., expert says 2Deadly fungus threatens 9 bat species in Ga., Ky., N.C., S.C. and Tenn., expert says 3
Recombinant Mouse IL-23, CF...
... ActivePro In Vitro Translation ... E.coli lysate, synthesizes higher ... well as proteins with ... competing kits. This results ...
... , Customer Peptide Synthesis , Containing one Phospho-Amino ... mg will be returned to customer conjugation of peptide to KLH ... Maintenance 102 days/each , Pre-immune bleed ... , Test bleed (app. 5 ml) x1 ...
Donor Goat Serum...
Biology Products: